Kossel Medtech

About Kossel Medtech

Established in 2013 by founder Navis Feng and a team of experts from both the US and China, Kessel Medical Technology (Suzhou) Co., Ltd. operates in the advanced medical device sector, specializing in Class III interventional cardiovascular products. The firm focuses on the research, development, manufacturing, and distribution of devices for coronary and peripheral intervention, as well as electrophysiology. Its business model is centered on B2B sales to domestic and international medical device manufacturers, distributors, and hospitals. Kessel Medical also offers OEM/ODM cooperation and contract manufacturing services for customized stents, leveraging its technical team and production lines.

The company's product portfolio is extensive, including PTCA and PTA balloon catheters, coronary stent systems, cardiac ablation catheters, and vena cava filters. A key product, the Selethru™ NC PTCA Balloon Dilatation Catheter, is a rapid exchange catheter designed to dilate stenotic portions of coronary arteries to improve myocardial perfusion. This device features radiopaque marker bands to aid in precise positioning during procedures. Kessel operates from a facility of over 20,000 square meters and has secured significant intellectual property rights with over 210 patents. The company has received numerous international certifications, including CE, FDA, KFDA, and PMDA, enabling it to serve a global client base across multiple continents.

Financially, Kessel Medical has demonstrated strong growth, attracting notable investment. The company secured a Series A funding round of $15.7 million in January 2022 and a Series B round exceeding 100 million RMB in December 2023, led by investors such as Fortune Capital and Medpark. These funds are intended to deepen its vascular intervention platform, expand its product pipeline and production base, and further its international layout. A key strategic move was the acquisition of Micell at the end of 2021 to accelerate its globalization strategy. The company has established several subsidiaries to manage different aspects of its business, including Suzhou Haiyu Medtech for tachycardia treatments and Mixin Medtech for coronary intervention product development.